论文部分内容阅读
目的:针对患有活动性胃溃疡患者行以雷贝拉唑和瑞巴派特,对比其所获得的临床效果。方法:随机在2013年3月到2017年5月期间我院接诊的患有活动性胃溃疡患者当中择取80名,将其分成实验组和参照组两组(n=40),对参照组行以奥美拉唑进行治疗,对实验组行以雷贝拉唑联合瑞巴派特进行治疗。观察分析两组患者的治疗效果。结果:经过不同的药物治疗措施,实验组的治疗效果好于参照组但是没有显著差异,P>0.05;另外,在两组患者的慢性炎症反应以及活动炎症反应评分上,治疗后存在显著差异,P<0.05。结论:在临床当中,对于患有活动性胃溃疡的患者行以雷贝拉唑同瑞巴派特联合的治疗措施,能够获得理想的治疗效果,值得推广。
OBJECTIVE: To compare the clinical efficacy of rabeprazole and rebamipide in patients with active gastric ulcer. Methods: Totally 80 patients with active gastric ulcer admitted to our hospital from March 2013 to May 2017 were randomly divided into two groups (n = 40) and the control group Group omeprazole treatment, the experimental group with rabeprazole and rebamipide treatment. Observation and analysis of the treatment effect of two groups of patients. Results: The treatment effect of the experimental group was better than that of the reference group through different drug treatment measures, but there was no significant difference (P> 0.05). In addition, there was significant difference between the two groups in chronic inflammatory reaction and active inflammatory response score after treatment, P <0.05. Conclusion: In clinical practice, the combination of rabeprazole with rebamipide in patients with active gastric ulcer can achieve the desired therapeutic effect and is worthy of popularization.